TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - AMGEN TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - AMGEN Share Price
Certificat
DE000SW1F7M4
| Delayed Deutsche Boerse AG 01:16:23 03/07/2024 pm IST | ||
| 13.43 EUR | -0.67% |
|
| Current month | +0.22% | ||
| 1 month | -3.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 13.43 | -0.67% |
| 02/24/02 | 13.52 | -0.29% |
| 01/24/01 | 13.56 | +0.52% |
| 28/24/28 | 13.49 | +0.22% |
| 27/24/27 | 13.46 | +0.45% |
Delayed Quote Deutsche Boerse AG
Last update July 03, 2024 at 01:16 pm IST
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | AMGEN INC. |
| Issuer | 
Société Générale
|
| WKN | SW1F7M |
| ISIN | DE000SW1F7M4 |
| Date issued | 25/07/2023 |
| Strike | 454.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 20.48 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.31 € |
|---|---|
| Lowest since issue | 12.09 € |
| Spread | 0.15 € |
| Spread % | 1.11% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
310.8
USD
Average target price
316.4
USD
Spread / Average Target
+1.82%
- Stock Market
- Certificates
- Certificat
